Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) announced the acceptance of a poster for presentation at the virtual ADCES 2020 Annual Conference from August 13-16, 2020. The poster titled "Impact of Digital Management on Clinical Outcome in Patients with Chronic Conditions: Diabetes and Hypertension" highlights a study with 345 participants using Dario's digital therapeutics platform. Results show a 70% improvement in blood pressure and significant reductions in glucose levels among users diagnosed with diabetes. The findings position Dario's platform as a valuable tool for managing chronic diseases.

DarioHealth Corp. (Nasdaq: DRIO) will announce its second quarter financial results for the period ending June 30, 2020, on August 12, 2020. Following the release, a conference call will be held at 9:00 AM EDT, featuring key executives including CEO Erez Raphael and CFO Zvi Ben-David. Participants can join the call using provided dial-in numbers, and a replay will be available shortly after the call until August 26, 2020. DarioHealth specializes in digital therapeutics, enhancing the management of chronic conditions through innovative technology.

DarioHealth Corp. (Nasdaq: DRIO) has successfully completed a private placement transaction, raising approximately $28.6 million from accredited investors in the U.S. and Israel. This funding positions the company at its best financial state since its inception, aiming to transition from a direct-to-consumer model to a more profitable business-to-business-to-consumer strategy. Proceeds will enhance commercial infrastructure and secure contracts with health plans and employers. The transaction closed on July 31, 2020, with shares priced at $7.47 and $7.94.

DarioHealth Corp. (Nasdaq: DRIO) has announced a strategic partnership with Williams Medical to launch its Remote Patient Monitoring (RPM) platform across the UK and Ireland. This initiative aims to assist healthcare professionals in managing chronic conditions, alleviating pressures from the COVID-19 pandemic. Dario's RPM solution enhances patient care while reducing healthcare provider workloads. The partnership leverages Williams Medical's extensive network of over 8,000 practices, enhancing Dario's growth strategy outside the U.S. and targeting chronic conditions like diabetes.

DarioHealth Corp. (Nasdaq: DRIO) announced the appointment of Dennis A. Matheis to its Board of Directors as of July 2, 2020. Matheis, president of Optima Health, brings nearly 30 years of healthcare experience. His expertise is expected to enhance Dario's transition to a business-to-business-to-consumer model, focusing on chronic disease management. DarioHealth is known for its digital therapeutic solutions, particularly its MyDario™ app, which is well-regarded in the market.

DarioHealth Corp. (Nasdaq: DRIO) will host a key opinion leader (KOL) call on June 23, 2020, at 10:30 a.m. ET, focusing on digital therapeutics for managing diabetes and chronic conditions. Dr. David Simmons will present on the role of digital therapeutics in enhancing standard care for diabetes patients. The company's SaaS platform aims to improve health outcomes while reducing costs through an integrated service that combines a medical device, mobile app, and coaching. For more details, register for the webcast here.

DarioHealth Corp. (Nasdaq: DRIO) announced its participation in the virtual Going Digital: Behavioral Tech Summit on June 17, 2020. Chief Medical Officer, Dr. Omar Manejwala, will present on "Behavioral Health at Scale" from 10:30-10:50 a.m. PT. The summit focuses on best practices for utilizing teletherapy and digital behavioral health solutions, especially in response to COVID-19. DarioHealth is recognized for its innovative digital therapeutics aimed at improving the management of chronic conditions through data-driven interventions, engaging software, and coaching.

DarioHealth Corp. (Nasdaq: DRIO) presented new study results at the ADA's 80th Scientific Sessions, highlighting its digital therapeutic platform's effectiveness. Key findings from a 12-month study with 9,200 Type-2 diabetes users showed a 26% reduction in high blood glucose events and significant improvements in blood pressure management, with 71% of hypertension users reducing systolic blood pressure. A separate 2-year study revealed an average 18% reduction in blood glucose. These results validate the platform's role in improving chronic condition management.